Blog mAbxience

presentation

Differences between substitution and interchangeability

3/17/2017

When a biosimilar drug is authorised by a regulatory agency, it means that it can be prescribed with guarantees over its efficacy and safety for all indications [...]

+

How an audit of compliance with Good Manufacturing Practices (GMP) is processed

2/27/2017

In light of the recent authorisation issued by the Spanish Agency for Medicines and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios - AEMPS) for the mAbxience [...]

+

Traceability and Pharmacovigilance

2/6/2017

Biosimilars, like all biological drugs, undergo special vigilance for a 5-year period after they are approved. Drugs subject to this vigilance period are marked with a black triangle. [...]

+

Differences between biosimilars and generic drugs

1/20/2017

One of the main problems that biosimilar drugs face is that many doctors and patients still cannot differentiate them from generic drugs, as they tend to believe [...]

+

Biosimilars' economic predictions according to experts

12/16/2016

The biological drugs market is rapidly growing, especially when compared to the chemical molecule drugs market. Proof of this lies in the fact that 9 out of [...]

+

Biosimilar medicines: access to clinical practice

12/7/2016

On 3rd November, the Health Research Foundation (Fundación para la Investigación en Salud - FUINSA) held a conference in Madrid to address the access of biosimilar medicines to clinical practice. Representatives from [...]

+

World Biosimilar Congress Europe 2016

11/28/2016

On 14th and 15th November 2016 the 5th World Biosimilar Congress was held in Basel (Switzerland). It addressed subjects like the pre-clinical and clinical development of biosimilars, the extrapolation of indications and interchangeability, [...]

+

Outlook on biosimilars

11/18/2016

There is no doubt that biological drugs are the treatment future for many pathologies. They can be used in areas such as oncology, diabetes or pain control. However, they are much more [...]

+

Influencing factors in the implementation of biosimilars

11/4/2016

A study conducted by the consultancy company GFK on behalf of the European Biosimilars Group analysed the main factors that support a sustainable European biosimilar drugs market [...]

+

Progression in the medium to long-term

10/28/2016

As we have been outlining so far in previous posts, three trends are anticipated in the medium to long-term in the progression of biosimilar drugs. These include [...]

+

The industry’s commitment: a long-distance race

10/18/2016

Introducing biosimilars onto the market is a very slow, expensive and risky process. Besides having to wait for the original drug or reference drug patents to expire, [...]

+

Economic impact according to experts

10/7/2016

As we have already mentioned in previous posts, several international consultants have conducted studies estimating the economic saving that biosimilars could generate for the Spanish national health [...]

+

Allies of the national healthcare system

9/30/2016

As we have already mentioned in previous posts, taking into account that the efficacy, safety and quality of biosimilar drugs are similar to that of their reference [...]

+

Entry barriers in healthcare systems

9/23/2016

Before drugs go on sale, they have to pass a series of technical and administrative controls, which are regulated by the Food and Drug Administration (FDA) in [...]

+

LYMPHOMA AND BIOLOGIC TREATMENTS

9/15/2016

Lymphoma is a malignant proliferation of lymphocytes that generally takes place in the lymph nodes, although other organs such as the liver, spleen or bone marrow may [...]

+

Contribution to healthcare expenditure and the government's response

9/8/2016

Biologics are obtained through genetic engineering processes which are characterised by high costs. In addition, they are used to treat diseases which have a significant economic impact [...]

+

The savings potential of biosimilars

8/31/2016

The last two content blocks allowed us to take a closer look at the real-life implication of biosimilars by offering insight into their social repercussions within the [...]

+

Biosimilars and their social repercussions and their accesibility

8/23/2016

At a time when the burden of chronic disease is increasing throughout the world, it is more important than ever to improve the health of the general [...]

+

A commitment to help patients with autoimmune diseases

7/27/2016

Autoimmune diseases represent a therapeutic area that, despite having lower incidences to that of cancer, often faces neglect. Such diseases affect 8% of the population with over [...]

+

The contribution of monoclonal antibodies in haematology

7/14/2016

As we have said in previous posts on the social impact of biosimilars, we can now see that both the pharmaceutical industry and national health systems are [...]

+

Biosimilars provide support in the fight against cancer

6/16/2016

Cancer features in all sector studies as one of the main causes of death around the world. In 2015, 227,000 new cancer cases were diagnosed in Spain, [...]

+

Biosimilars and their social repercussions

6/8/2016

The key role of accessibility   The purpose of the second part of this blog is to investigate the social repercussions of biosimilars. This and upcoming posts will assess [...]

+

Biosimilar's manufacturing process

5/24/2016

How is a biosimilar manufactured?   Along the lines of the previous post, in which we explained the steps leading to the development of a biosimilar, the aim of [...]

+

An examination of biosimilars and mAbs

5/6/2016

The aim of this post is to explain how a biosimilar is developed. It has to be said that the process involves a certain amount of complexity [...]

+

A long history: An introduction to biosimilars and monoclonal antibodies (mAbs)

4/25/2016

As we mentioned in the last post, biopharmaceuticals encompass all substances used to treat a disease that are solely and exclusively extracted from living creatures. The interesting [...]

+

What are mAbs biosimilars?

4/7/2016

An introduction to biosimilars and monoclonal antibodies (mAbs)   The purpose of this second post is to provide a simplified yet accurate introduction to biosimilars.   The first thing to know [...]

+

INITIATIVE: "WE PROMOTE BIOSIMILARS"

1/25/2016

mAbxience is more than aware that the biggest limitation for progress and innovation is lack of knowledge, which has a direct effect in the case of biosimilars. In view of this, the company strives to inform people and, more importantly, shed light on the entity, origin and evolution of biosimilars in society, so that they can be better understood.
+